Monte Rosa Therapeutics

Small molecule cancer drugs that modulate protein degradation pathways

Undisclosed Clin0 autoimmune disease; 4 undisclosed programs RD inflammatory diseases, multiple cancers, sickle cell disease, B-thalassemia, undisclosed

Monte Rosa Therapeutics is a biopharmaceutical company in Boston, MA, developing a new class of drugs called molecular glue degraders (MGDs) to fight cancer, autoimmune diseases, and inflammatory diseases. MGDs utilize the body's natural protein degradation pathways, including the ubiquitin-proteasome system, to eliminate therapeutically relevant proteins. MGDs bind to ubiquitin ligases complementary to the target protein, to tag the protein for degradation via the proteasome. These therapies have the potential to eliminate proteins considered to be “undruggable.” Their platform, called QuEEN (Quantitative and Engineered Elimination of Neosubstrates), allows the rapid identification of protein targets and design of MGD drug candidates.